Targeted therapy for triple-negative breast cancer: Where are we?

被引：82

作者：

Duffy, Michael J. ^{[1
,2
]}

McGowan, Patricia M. ^{[2
]}

Crown, John ^{[3
,4
]}

机构：

[1] St Vincents Univ Hosp, UCD Clin Res Ctr, Dublin 4, Ireland

[2] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, UCD Sch Med & Med Sci, Dublin 4, Ireland

[3] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland

[4] St Vincents Univ Hosp, Dept Med Oncol, Dublin 4, Ireland

来源：

INTERNATIONAL JOURNAL OF CANCER | 2012年 / 131卷 / 11期

基金：

爱尔兰科学基金会;

关键词：

triple-negative breast cancer; biomarkers; predictive markers; PARP; GROWTH-FACTOR RECEPTOR; POLY(ADP-RIBOSE) POLYMERASE INHIBITION; CELL-LINES; PTEN LOSS; MOLECULAR CHARACTERIZATION; MUTANT-CELLS; OPEN-LABEL; BASAL; DASATINIB; TUMOR;

D O I：

10.1002/ijc.27632

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancers that are negative for estrogen receptor (ER), progesterone receptors (PR) and HER2, using standard clinical assays, have been dubbed triple-negative (TN). Unlike other molecular subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer. Preclinical studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2). Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer. The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.

引用

页码：2471 / 2477

页数：7

共 91 条

[71] Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells [J].

Pichot, C. S. ;

Hartig, S. M. ;

Xia, L. ;

Arvanitis, C. ;

Monisvais, D. ;

Lee, F. Y. ;

Frost, J. A. ;

Corey, S. J. .

BRITISH JOURNAL OF CANCER, 2009, 101 (01) :38-47

[72] Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer [J].

Ponzo, Marisa G. ;

Lesurf, Robert ;

Petkiewicz, Stephanie ;

O'Malley, Frances P. ;

Pinnaduwage, Dushanthi ;

Andrulis, Irene L. ;

Bull, Shelley B. ;

Chughtai, Naila ;

Zuo, Dongmei ;

Souleimanova, Margarita ;

Germain, David ;

Omeroglu, Atilla ;

Cardiff, Robert D. ;

Hallett, Michael ;

Park, Morag .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (31) :12903-12908

[73] Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer [J].

Prat, Aleix ;

Parker, Joel S. ;

Karginova, Olga ;

Fan, Cheng ;

Livasy, Chad ;

Herschkowitz, Jason I. ;

He, Xiaping ;

Perou, Charles M. .

BREAST CANCER RESEARCH, 2010, 12 (05)

[74] Prognostic markers in triple-negative breast cancer [J].

Rakha, Emad A. ;

El-Sayed, Maysa E. ;

Green, Andrew R. ;

Lee, Andrew H. S. ;

Robertson, John F. ;

Ellis, Ian O. .

CANCER, 2007, 109 (01) :25-32

[75] Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes [J].

Rakha, Emad A. ;

Elsheikh, Somaia E. ;

Aleskandarany, Muhammed A. ;

Habashi, Hany O. ;

Green, Andrew R. ;

Powe, Desmond G. ;

El-Sayed, Maysa E. ;

Benhasouna, Ahmed ;

Brunet, Jean-Sebastien ;

Akslen, Lars A. ;

Evans, Andy J. ;

Blamey, Roger ;

Reis-Filho, Jorge S. ;

Foulkes, William D. ;

Ellis, Ian O. .

CLINICAL CANCER RESEARCH, 2009, 15 (07) :2302-2310

[76] Histone yH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers [J].

Redon, Christophe E. ;

Nakamura, Asako J. ;

Zhang, Yong-Wei ;

Ji, Jiuping ;

Bonner, William M. ;

Kinders, Robert J. ;

Parchment, Ralph E. ;

Doroshow, James H. ;

Pommier, Yves .

CLINICAL CANCER RESEARCH, 2010, 16 (18) :4532-4542

[77] PARP inhibition: PARP1 and beyond [J].

Rouleau, Michele ;

Patel, Anand ;

Hendzel, Michael J. ;

Kaufmann, Scott H. ;

Poirier, Guy G. .

NATURE REVIEWS CANCER, 2010, 10 (04) :293-301

[78] Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms [J].

Rowe, Bryan P. ;

Glazer, Peter M. .

BREAST CANCER RESEARCH, 2010, 12 (02)

[79] Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up [J].

Ryden, Lisa ;

Jirstrom, Karin ;

Haglund, Monica ;

Stal, Olle ;

Ferno, Marten .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (02) :491-498

[80] Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair [J].

Saal, Lao H. ;

Gruvberger-Saal, Sofia K. ;

Persson, Camilla ;

Loevgren, Kristina ;

Jumppanen, Mervi ;

Staaf, Johan ;

Jonsson, Goeran ;

Pires, Maira M. ;

Maurer, Matthew ;

Holm, Karolina ;

Koujak, Susan ;

Subramaniyam, Shivakumar ;

Vallon-Christersson, Johan ;

Olsson, Hakan ;

Su, Tao ;

Memeo, Lorenzo ;

Ludwig, Thomas ;

Ethier, Stephen P. ;

Krogh, Morten ;

Szabolcs, Matthias ;

Murty, Vundavalli V. V. S. ;

Isola, Jorma ;

Hibshoosh, Hanina ;

Parsons, Ramon ;

Borg, Ake .

NATURE GENETICS, 2008, 40 (01) :102-107

← 1 2 3 4 5 6 7 8 9 10 →